A group from University of Chicago Medicine urged physicians to consider testing for HHV-6 in cases of unexplained liver failure in immunocompetent patients, especially those with skin rash and upper respiratory symptoms, citing evidence from past studies as well as their own recent case experience.
High prevalence of HHV-6B & HPV in invasive pituitary adenomas
A recent study from investigators at Chongqing University in China explored the involvement of three viruses in the progression of pituitary adenomas (PA). The authors suggest that the HPV-16 and HHV-6 viruses activate the TLR3/ NF-kB signaling pathway which in turn contributes to the progression and proliferation of invasive pituitary adenomas.
Superinfection of HHV-6A in ciHHV6A patients with recurrent cardiac disease: a full genome analysis
A group led by Ursula Gompels from the London School of Hygiene & Tropical Medicine, University of London, did next generation sequencing on three ciHHV6A cardiac patients and found superinfections of HHV-6A in two of the three. They characterized the first full genome sequence of ciHHV-6A and demonstrated the inherited ciHHV6 genome was similar but distinct from known exogenous (community acquired) strains of HHV-6A .
HHV-6 & 7 potentiate CMV infection in transplant patients
A new study suggests that HHV-6 and HHV-7 are important co-factors for the development of CMV infection post-transplant in allogeneic hematopoietic stem cell transplantation patients. Additionally, the presence of HHV-7 and CMV together may result in more severe infections than either virus alone.
Joshua Hill wins the HHV-6 Foundation Caroline B. Hall Young Investigator Award
Dr. Joshua Hill, a research associate in Fred Hutch’s Vaccine and Infectious Disease Division, was awarded the Caroline B. Hall Young Investigator Award at the International HHV-6 & 7 Conference in Boston for his work on HHV-6.
Brincidofovir fails Phase III CMV trial. Did physicians mistake diarrhea for GVHD?
Chimerix announced that the Phase III trial of brincidofovir has failed to meet its primary endpoint of suppressing CMV infection through week 24 after hematopoietic cell transplant (HCT) patients. Although the drug showed impressive suppression of CMV infections during the 14 week trial, infections soared during the 10-week observation period that followed. One theory presented by the company’s CEO is that physicians may have mistaken drug related diarrhea for GHVD and administered unnecessary steroids.
Specific NK Cell subsets Associated with HHV-6 Infection in Hashimoto’s Thyroiditis
Human herpesvirus-6 (HHV-6) has been associated with several autoimmune diseases. A recent study led by Rizzo and Caselli have found a possible link to Hashimoto’s Thyroiditis (HT). They report that HHV-6 infection correlated with higher levels of a particular type of NK cell associated with a potent release of cytokines.
Higher Loads of HHV-6B Found in the Brain Autopsies of Patients with Unspecified Encephalopathy
Autopsy brain samples from 51 controls and 57 patients who died with encephalopathy of unknown origin were tested for HHV-6 & HHV-7 using immunohistochemistry, nested and real time PCR.
Fatal HHV-6 pediatric myocarditis following immunosuppression
A case report published by a group at the University of Minnesota details two cases of fatal myocarditis associated with HHV-6 in two immunosuppressed children.
HHV-6B found in 6% of chronic and recurrent lymphadenopathy cases
A group of Italian investigators have determined that a subset of patients with lymphadenopathy have active HHV-6B infections.
Bhupesh Prusty earns Young Investigator Award for Excellence in Basic Science
Dr. Bhupesh Prusty, PhD, Group Leader in the Department of Microbiology at the University of Würzburg in Germany was recently awarded the Koichi Yamanishi Young Investigator Award for Excellence in Basic Science.
Philip Pellett wins Lifetime Achievement Award
Philip Pellett, PhD, a Professor and Interim Chair of Immunology and Microbiology at the Wayne State University School of Medicine, was awarded the HHV-6 Foundation’s Dharam Ablashi Lifetime Achievement Award at the 9th International Conference on HHV-6 & 7.
Immunodominant HHV-6B proteins identified using a proteomics approach
Instead of using the traditional epitope mapping approach to identify major targets of the T cell response to a complex pathogen, a group from the University of Massachusetts used mass spectrometry to identify viral proteins associated with immunodominant antigens.
Conference Videos
Thank you to the presenters who agreed to make their presentations at the 9th International Conference on HHV-6 & 7 available to others. HHV-6 ANTIVIRAL THERAPY The Difficult Path Towards an HHV-6 Therapy Lieve Naesens, PhD, Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Belgium DIAGNOSTICS Diagnostic Tools and Algorithms for HHV-6 Infections in Immunocompromised Patients Agnes Gautheret Dejean, …